Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL

Opinion
Video

A panel of oncology experts offer insights into key consideration factors for BTKi selection for CLL in the relapsed and refractory setting, exploring the impact of emerging MAIC data on treatment decision making.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
Related Content
HCT Rates Increase Across Ethnic/Racial Subgroups in Multiple Myeloma, Lymphoma

HCT Rates Increase Across Ethnic/Racial Subgroups in Multiple Myeloma, Lymphoma

May 6th 2024
Article

Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

July 6th 2020
Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Mobile App May Facilitate GVHD Symptom Management

Mobile App May Facilitate GVHD Symptom Management

April 27th 2024
Article

A mobile app may help to expedite treatment and identification for patients with GVHD.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation

April 26th 2024
Article

Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.

New Tocilizumab Workflow Is More Effective for CRS Related to CAR T, Bispecific Antibodies

April 26th 2024
Article

A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.